IL6 and atherosclerosis: Apart from this, the multicenter randomized control (CANTOS) trial by Ridker et al. demonstrated that an anti-inflammatory drug, canakinumab, which targets cytokines IL-1 and IL-6, could decrease ASCVD events [45,46].